Background: Moderate to severe plaque psoriasis (with or without psoriatic arthritis) places significant burden on patients lives. This was a US-based, multicenter, non-interventional, narrative study to evaluate patient-reported experiences of living with moderate to severe plaque psoriasis, with or without PsA. This observational study was non-interventional; therefore, any administration of therapies to patients by study investigators was part of usual care. An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis. Clinical Trials2012. Tweet this; Star this. We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis. We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis.
Before the frst biologic was FDA approved for psoriasis, treatment options consisted of topical agents, phototherapy and conventional systemic agents. Evaluation of Adalimumab Every Other Week in Moderate to Severe Psoriasis Trial) study, 1,212 patients were randomized to receive adalimumab 40 mg subcutaneously or placebo every other week for 15 weeks. An observational study of 2,151 patients with plaque psoriasis demonstrated clinical improvement and treatment satisfaction with biologics compared with other therapies. The design and utility of PSOLAR have been reported previously. An observational study of the real-life management of psoriasis patients treated with etanercept according to the new reimbursement criteria (in Belgium).
Of note, a minority of patients reported a high consumption of topical treatment. (HRQOL), ranging from physical discomfort and limitations in activities of daily living to psychosocial problems and emotional distress 3 7. As new therapies become available for managing psoriasis, it is important to evaluate their impact on patient-reported HRQOL. The study enrolled patients with moderate to severe plaque psoriasis and results may not be applicable to patients with other forms of psoriasis. From the studies that reported psoriasis severity, the pooled OR for obesity among patients with mild psoriasis was 1. In this systematic review and meta-analysis of observational studies, we synthesized the current literature on the association between psoriasis and obesity based on epidemiological studies from around the world. To be eligible for inclusion in the systematic review, the original studies needed to fulfill the following criteria: case control, cross-sectional, cohort or nested case control design; evaluation of obesity in conjunction with psoriasis; and analyses that compared psoriasis patients with control groups.
An Overview Of Biologics
About 35 of patients with psoriasis have one or more family members with the disorder. Treatment options for moderate to severe psoriasis include topical and systemic medications, phototherapy, and excimer laser, Combination therapies are often more effective than one treatment alone. Several new agents to treat psoriasis are under study, including oral medications and injectable agents. Ustekinumab is approved in multiple countries for the treatment of adults with chronic moderate-to-severe plaque psoriasis. The dermatology life quality index (DLQI) is a 10-item, patient-reported, quality-of-life questionnaire.